Zheng Xiaomeng, Tong Chengbi, Li Xiaodong, Meng Yanan, Liu Xiaodan
Xiaomeng Zheng Clinical Laboratory, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Chengbi Tong Clinical Laboratory, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Pak J Med Sci. 2024 Dec;40(11):2626-2630. doi: 10.12669/pjms.40.11.9564.
To investigate the clinical value of EGFR mutation testing in peripheral blood of patients with non-small cell lung cancer.
This was a retrospective study. A total of 89 patients with non-small cell lung cancer (NSCLC) admitted to Affiliated Hospital of Hebei University between June 2019 and May 2023 were selected, and divided into the wild-type group and the mutant group according to the results of EGFR mutation testing in peripheral blood. Clinic pathological data of patients were collected and compared between the two groups, the correlation between EGFR mutation and the prognosis was analyzed.
No statistically significant difference in the mutation rate of EGFR gene was observed between peripheral blood ctDNA and tumor tissue (p=0.879). EGFR mutation in peripheral blood ctDNA was not significantly correlated with sex, age, ethnicity and ECOG score (p>0.05). The EGFR mutation rate was increased in patients with adenocarcinoma compared with that in patient with squamous carcinoma, and in non-smoking patients compared with that in smoking patients, and the differences were statistically significant (p<0.05). The 1-, 2-, and 3-year disease-free survival (DFS) rates were significantly increased in the mutant group compared with those in the wild-type group, respectively (p<0.05).
EGFR mutation in peripheral blood and tumor tissues is highly consistent in NSCLC patients. The EGFR mutation rate is higher in adenocarcinoma and non-smoking patients, and the prognosis is better in patients with EGFR mutations.
探讨非小细胞肺癌患者外周血表皮生长因子受体（EGFR）突变检测的临床价值。
本研究为回顾性研究。选取2019年6月至2023年5月在河北大学附属医院住院的89例非小细胞肺癌患者，根据外周血EGFR突变检测结果分为野生型组和突变型组。收集两组患者的临床病理资料并进行比较，分析EGFR突变与预后的相关性。
外周血循环肿瘤DNA（ctDNA）与肿瘤组织中EGFR基因的突变率差异无统计学意义（p = 0.879）。外周血ctDNA中的EGFR突变与性别、年龄、种族及美国东部肿瘤协作组（ECOG）评分无明显相关性（p > 0.05）。腺癌患者的EGFR突变率高于鳞癌患者，非吸烟患者的EGFR突变率高于吸烟患者，差异有统计学意义（p < 0.05）。突变型组的1年、2年和3年无病生存率（DFS）分别显著高于野生型组（p < 0.05）。
非小细胞肺癌患者外周血与肿瘤组织中的EGFR突变具有高度一致性。腺癌和非吸烟患者的EGFR突变率较高，EGFR突变患者的预后较好。
